Objective: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard.

Methods: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria. Cut-off values for changes in interim and post-treatment FDG uptake (ΔSUV) in the prediction of progression-free survival (PFS) were measured using ROC analysis. Quantitative and visual data were compared with each other in the prediction of PFS.

Results: Mean interim and post-treatment ΔSUV of the primary lesions were 77.4 ± 19.5 and 68.8 ± 30.4% and respective cut-off values were 82 and 73%. However, only post-treatment ΔSUV yielded statistically significant results in the prediction of 3-year PFS (p = 0.043). Interim ΔSUV was further analyzed according to the values reported in the literature (66 and 77%) yet statistically significant results were not reached (p = 0.604 and 0.431). For interim evaluation, IHP criteria was correlated to Deauville criteria (p = 0.002 and p = 0.001) and ΔSUV (p = 0.03), whereas for post-treatment evaluation, significant correlation with ΔSUV (p = 0.04) but marginally significant (p = 0.055 and p = 0.058) correlation with Deauville criteria were achieved. Overall, 1, 3 and 5-year PFS were 95.7 ± 0.2, 89.6 ± 0.4 and 80.8 ± 0.7%, respectively. All methods demonstrated comparable performance in the prediction of 3-year PFS; however, interim PET using Deauville criteria and post-treatment PET using IHP criteria were statistically significant. All methods demonstrated high negative-predictive value but substantially low positive-predictive value.

Conclusions: Deauville criteria are superior to other methods in the prediction of pediatric HL outcome using interim PET data. On the other hand, quantitative evaluation and visual evaluation by IHP can be used reliably at the end of the treatment. In this regard, we report the optimal cut-off value of SUV reduction as 73%.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-017-1196-xDOI Listing

Publication Analysis

Top Keywords

deauville criteria
20
ihp criteria
12
interim post-treatment
12
criteria
10
pediatric hodgkin
8
hodgkin lymphoma
8
post-treatment pet
8
cut-off values
8
post-treatment Δsuv
8
prediction 3-year
8

Similar Publications

Prognostic value of interim [F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.

Eur Radiol

January 2025

Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

Purpose: To evaluate the prognostic value of interim [F]Fluorodeoxyglucose positron emission tomography/computed tomography ([F]FDG PET/CT) after immunotherapy-based systemic therapies in extranodal natural killer/T-cell lymphoma (ENKTL).

Patients And Methods: We retrospectively recruited 133 newly diagnosed nasal-type ENKTL patients who underwent interim [F]FDG PET/CT scans after 2-4 cycles of immunotherapy-based treatments. Interim PET/CT was interpreted by maximum standardized uptake value (SUV), Deauville 5-point scale (DS), and early treatment response.

View Article and Find Full Text PDF

Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma, and many indolent/low-grade NHLs such as follicular lymphoma. Apart from these routinely FDG-avid lymphomas, some indolent NHLs, such as marginal zone lymphoma, are variably FDG-avid; here, [F]FDG PET/CT is an alternative to contrast-enhanced CT at baseline and may be used for treatment response assessment if the lymphoma was FDG-avid at baseline.

View Article and Find Full Text PDF

Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.

BMC Cancer

December 2024

Department of Nuclear Medicine, School of Medicine, Shanghai General Hospital, Shanghai JiaoTong University, Shanghai, 200080, China.

Background: This study aimed to identify the prognostic value of interim F-FDG PET/CT (I-PET) for germinal center B-cell-like (GCB) and non-GCB diffuse large B-cell lymphoma (DLBCL), respectively.

Methods: Baseline F-FDG PET/CT (B-PET) and I-PET scans were performed in 112 patients with DLBCL. The prognostic value of I-PET using the Deauville five-point scale (D-5PS) criteria or percentage decrease in SUVmax (∆SUVmax) for GCB and non-GCB DLBCL were evaluated.

View Article and Find Full Text PDF

The risk of cytokine release syndrome (CRS) in patients with infections prior to chimeric antigen receptor T-cell (CAR T-cell) therapy represents an important and underreported event. Patients with active infections needing prompt CAR T-cell therapy to treat aggressive hematologic malignancies remain a clinical challenge. This case describes the clinical course of a 35-year-old male patient with relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma who received axicabtagene ciloleucel.

View Article and Find Full Text PDF

Assessing the intracranial metabolic score as a novel prognostic tool in primary CNS lymphoma with end of induction-chemotherapy F-FDG PET/CT and PET/MR.

Cancer Imaging

November 2024

Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.

Article Synopsis
  • This study investigates the prognostic value of a new scoring system called the intracranial metabolic score (IMS) in patients with primary central nervous system lymphoma (PCNSL) who undergo end-of-therapy imaging using F-FDG PET/CT and PET/MR.
  • The IMS is based on the metabolism of normal brain structures and was shown to outperform the traditional Deauville score (DS) in predicting progression-free survival (PFS) and overall survival (OS).
  • Results from the study suggest that a higher IMS score is associated with worse patient outcomes, confirming the IMS as a valuable prognostic tool for assessing PCNSL treatment effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!